摘要
目的:观察分析基于多种免疫细胞的细胞免疫疗法联合含硼替佐米的化疗方案治疗多发性骨髓瘤患者的临床效果。方法:选取2012年10月-2013年10月在我院住院治疗的76例多发性骨髓瘤患者,随机将他们分为2组,1组(38例)采用细胞免疫疗法联合含硼替佐米化疗方案(复合治疗组),另1组(38例)采用含硼替佐米的单纯化疗方案(单纯化疗组),比较2组患者治疗缓解率、免疫表型表达水平变化、无进展生存期(PFS)及不良反应发生情况。结果:复合化疗组总缓解率明显高于单纯化疗组(P<0.05);治疗后复合治疗组患者CD38^+、CD56^+、CD138^+和MRD^+表达率均明显低于单纯化疗组,CD19^+表达率均明显高于单纯化疗组(P<0.05);复合治疗组1、2、3年PFS均明显长于单纯化疗组(P<0.05);复合治疗组乏力、皮疹、周围神经病变、贫血、粒细胞缺乏等方面不良反应发生率均明显低于单纯化疗组(P<0.05)。结论:细胞免疫治疗联合含硼替佐米的化疗方案可显著增加多发性骨髓瘤患者的临床治疗疗效,明显提高缓解率的同时显著延长这类患者的生存期,而且可降低部分患者的不良反应的发生率,增加患者的化疗耐受。
Objective： To study the clinical efficacy of cellular immunotherapy combined with bortezomib for treatment of patients with multiple myeloma. Methods： A total of 76 patients with multiple myeloma in our hospital from October 2012 to October 2013 were selected and randomly divided into 2 groups： the patients in 1 group （38 cases） were treated with cellular immunotherapy combined with chemotherapy including bortezomib （ combined therapy group）, the patients in other group（38 cases） were treated with only chemotherapy including bortezomib（ single chemotherapy as control group）. The treatment remission rate, the expression changes of immunophenotype, progression-free survival （PFS） and adverse reactions were compared in the 2 groups. Results： The total remission rate of combined therapy group was significantly higher than that in the control group （ P 〈 0.05 ） ; the positive rates of CD38＋ , CD56＋ and CD138 ＋ in combined therapy group were all significantly lower than those in control group, and the CD19＋ was significantly higher （ P 〈 0.05 ）. The PFS rates of 1, 2 and 3 years in the combined therapy group were all significantly higher than those in the control group （P 〈 0.05 ）. The incidence of fatigue, rash, peripheral neuropathy, anemia and granulocyte deficiency in the combined therapy group was all significantly lower than that in the control group （P 〈 0. 05）. Conclusion： Cellular immunotherapy combined with bortezomib can significantly improve the remission rate, prolong survival, and significantly decrease adverse event rate of multiple myeloma patients.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2017年第3期818-822,共5页
Journal of Experimental Hematology
关键词
多发性骨髓瘤
细胞免疫治疗
硼替佐米
化疗
multiple myeloma
cellular immunotherapy
bortezomib
total body irradiation
chemotherapy
